Stay updated on Cabozantinib for NSCLC Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for NSCLC Brain Metastases Clinical Trial page.

Latest updates to the Cabozantinib for NSCLC Brain Metastases Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe study record for a cabozantinib trial in non-small cell lung cancer with brain metastases is displayed instead of an access-denied page. It includes study details and results information, eligibility criteria, and a notice that the trial was terminated due to slow patient accrual.SummaryDifference58%

- Check19 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0 on the error page.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces an NIH terminology transition, saying that federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) under Executive Order 14434.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details, with an error header visible. This indicates that the study record is currently inaccessible and the content is replaced by an access-denied message.SummaryDifference20%

Stay in the know with updates to Cabozantinib for NSCLC Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for NSCLC Brain Metastases Clinical Trial page.